concept
gene
deliveri
lung
therapeut
well
prevent
purpos
appear
straight
forward
rel
easi
applic
meet
patient
complianc
direct
access
target
tissu
low
enzymat
activ
compar
oral
rout
applic
absenc
ph
gradient
howev
simpl
concept
devil
detail
case
somebodi
put
correctli
three
challeng
afflict
effort
drug
develop
deliveri
deliveri
deliveri
first
deliveri
aspect
deposit
aerosol
dna
bear
particl
correct
site
lung
maintain
dna
integr
lieu
shear
forc
necessari
produc
aerosol
droplet
size
suitabl
inhal
second
enabl
uptak
dna
carrier
system
possibl
correct
target
cell
last
aspect
relat
obtain
success
transfect
ie
success
express
process
protein
encod
dna
deliv
three
stage
technolog
develop
sever
decad
chapter
would
like
focu
suppli
reader
overview
aspect
nonvir
dna
deliveri
gene
therapi
dna
vaccin
lung
first
report
pulmonari
deliveri
aerosol
dna
complex
cation
liposom
describ
stribl
et
al
use
dotma
n
dioleyloxi
propyl
n
n
ntriethylammonium
combin
fusigen
lipid
dope
dioleoylphosphatidylethanolamin
form
complex
pdna
encod
chloramphenicol
acetyl
transferas
cat
success
transfect
pulmonari
tissu
mice
achiev
absenc
toxic
side
effect
case
aerosol
achiev
nebul
turn
rather
ineffici
process
applic
aerosol
maintain
total
durat
h
aerosol
mg
total
dna
final
deposit
lung
howev
studi
spark
interest
aerosol
deliveri
pdna
number
genet
diseas
includ
cystic
fibrosi
cf
lung
cancer
inflammatori
afflict
lung
asthma
first
trial
becam
also
clear
nebul
larg
rel
fragil
molecul
pose
challeng
especi
seen
forc
necessari
produc
droplet
size
suitabl
inhal
shear
stress
occur
nebul
minim
order
maintain
structur
integr
dna
deliv
recent
paper
lentz
et
al
investig
effect
strain
rate
integr
plasmid
dna
pdna
aerosol
differ
deliveri
system
ultrason
vibrat
mesh
jet
nebul
electrostat
spray
strain
rate
defin
deriv
veloc
du
correl
linear
distanc
travel
dy
documentclass
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
gamma
text
utext
end
document
studi
reveal
lowest
destabil
effect
pdna
aerosol
electrostat
spray
highest
jet
nebul
spite
rel
low
strain
rate
also
vibrat
mesh
nebul
exert
destabil
effect
plasmid
dna
possibl
due
interact
molecul
vibrat
grid
alreadi
shown
dna
degrad
ultrason
nebul
due
cavit
ie
collaps
air
bubbl
creat
shock
wave
damag
dna
contrast
aerosol
nake
dna
complex
posit
charg
molecular
entiti
condens
compact
dna
shown
lead
stabil
dna
deliv
besid
result
potenti
increas
transfect
effici
observ
nonvir
deliveri
dna
usual
condens
electrostat
interact
either
cation
lipid
form
socal
lipoplex
cation
polym
polyplex
exampl
former
addit
mention
dotmadop
liposom
n
ethan
carbamoyl
cholesterol
dccholesterol
use
applic
plasmid
express
cystic
fibrosi
transmembran
conduct
regul
cftr
protein
mice
sinc
number
lipoplex
formul
develop
success
test
anim
clinic
trial
howev
lipoplexmedi
transfect
pulmonari
tissu
suffer
compar
low
effici
well
proinflammatori
side
effect
recent
use
improv
lipid
genzym
lipid
call
goldstandard
pulmonari
gene
deliveri
result
increas
transient
transfect
express
report
gene
instil
mous
lung
lipid
consist
spermin
headgroup
coval
attach
cholesterol
anchor
use
liposom
formul
includ
dioleoylphosphatidyl
ethanolamin
dope
dimyristoylphosphatidyl
ethanolamin
dmpe
polyethylen
glycol
peg
also
test
clinic
studi
cf
patient
treatment
result
signific
though
partial
restor
chlorid
channel
activ
disturb
cf
express
cftr
protein
anoth
cation
lipid
bgtc
show
rel
high
transfect
effici
vitro
vivo
use
combin
dope
appli
aerosol
mice
express
report
gene
cat
howev
lower
polyplex
prepar
polyethyleneimin
pei
appli
rout
addit
cytokin
tnfalpha
beta
level
measur
bronchoalveolar
fluid
balf
exposur
higher
bgtcbase
system
pei
polyplex
inflammatori
side
effect
lipoplexmedi
gene
deliveri
lung
attribut
cation
lipid
presenc
exposur
cpg
sequenc
absent
mammalian
present
bacteri
plasmid
dna
sequenc
identifi
ligand
tolllik
receptor
tlr
tlr
belong
group
pathogen
pattern
recognit
receptor
part
innat
immun
system
tlr
ligand
therefor
recent
introduc
novel
adjuv
boost
mucos
immun
respons
follow
pulmonari
applic
vaccin
see
polym
long
use
condens
dna
form
condens
polyplex
held
togeth
electrostat
forc
neg
charg
dna
posit
charg
polym
condens
reduc
size
dna
deliv
mask
neg
charg
factor
make
dna
amen
endocytosi
target
cell
cation
polym
especi
pei
may
also
assist
endosom
escap
ie
releas
intact
plasmid
dna
endosom
compart
depict
fig
case
polym
act
proton
spong
virtu
proton
multipl
amino
group
turn
buffer
ph
endosom
compart
caus
endosom
membran
ruptur
releas
polyplex
cytoplasm
addit
condens
polym
shown
stabil
dna
enzymat
degrad
exampl
wide
use
polym
nonvir
gene
deliveri
poli
llysin
pll
pei
poli
dimethylaminoi
ethylmethacryl
pdmaema
well
biodegrad
polysaccharid
chitosan
deriv
among
pei
pll
chitosan
fig
respect
deriv
shown
success
transfect
lung
epitheli
cell
vitro
vivo
pei
show
high
densiti
primari
secondari
tertiari
amin
function
structur
fig
therefor
suit
condens
dna
plasmid
act
proton
spong
lysosom
escap
facilit
intracellular
traffick
vector
pei
therefor
consid
nonvir
deliveri
system
gene
therapi
cf
genet
diseas
caus
aberr
chlorid
channel
protein
cftr
protein
express
mucos
epithelia
intestin
tract
lung
caus
fatal
link
pulmonari
effect
cf
gene
therapi
applic
correct
gene
aerosol
attempt
earli
regard
pei
shown
protect
dna
degrad
aerosol
process
lead
higher
transfect
rate
compar
cation
lipid
transfect
use
pei
polyplex
inhibit
lung
surfact
howev
pei
significantli
cytotox
appear
depend
densiti
posit
charg
well
molecular
weight
polym
degre
molecular
branch
cytotox
pei
aggreg
tendenc
peidna
complex
could
greatli
reduc
graft
pei
peg
reduct
cytotox
depend
degre
peg
graft
molecular
weight
peg
recent
studi
branch
pei
compar
newli
develop
copolym
oligo
ethylen
glycol
methyl
ether
methacryl
oegma
poli
n
ndimethylaminoethylmethacryl
pdmaema
term
toxic
transfect
effici
intratrach
applic
balbc
mice
copolym
could
prevent
polyplex
aggreg
high
concentr
isoton
solut
render
formul
use
vivo
applic
gene
express
vivo
appar
improv
sevenfold
compar
branch
pei
condens
plasmid
dna
polyllysin
pll
appear
depend
interact
primari
amin
group
polym
neg
charg
dna
format
stabl
polyplex
number
amin
group
avail
appear
crucial
import
polyplex
form
pll
molecular
weight
kda
shown
unstabl
hand
polyplex
prepar
high
molecular
weight
pll
tend
form
aggreg
isoton
solut
exert
consider
cytotox
overcom
challeng
pll
graft
peg
result
block
copolym
polyplex
form
copolym
maintain
stabil
serum
appli
suspens
concentr
exceed
mgml
dna
isoton
salin
success
pegpll
polym
employ
preclin
studi
mice
transfect
epitheli
cell
line
bronchial
tract
singl
intratrach
applic
base
favor
data
first
clinic
trial
initi
test
applic
plasmid
express
cftr
protein
condens
pegyl
pll
total
cf
patient
placebocontrol
doubleblind
doseescal
intranas
studi
primari
endpoint
safeti
toler
met
secondari
endpoint
gene
transfer
effici
assess
well
partial
complet
respons
seen
eight
subject
correct
persist
day
patient
even
week
singl
nasal
applic
polyplex
formul
chitosan
linear
cation
polysaccharid
consist
randomli
distribut
link
dglucosamin
deacetyl
unit
nacetyldglucosamin
acetyl
unit
industri
produc
alkalin
deacetyl
chitin
structur
element
exoskeleton
crustacean
degre
deacetyl
chitosan
rang
differ
molecular
weight
rang
da
viscos
grade
market
primari
amino
function
afford
possibl
easili
alter
chemic
modif
chitosan
pk
valu
amino
group
determin
around
vari
significantli
even
differ
degre
nacetyl
henc
chitosan
posit
charg
solubl
acid
solut
wherea
unmodifi
chitosan
insolubl
physiolog
ph
valu
chitosan
consid
serv
vector
gene
deliveri
due
biocompat
biodegrad
studi
dedic
unravel
relationship
structur
chitosan
ie
molecular
weight
degre
deacetyl
toxic
vitro
transfect
effici
intratrach
administr
mice
perform
recent
shown
percentag
deacetyl
must
greater
achiev
stabl
complex
plasmid
dna
achiev
transgen
express
term
acut
toxic
measur
incub
cell
valu
mgml
measur
ultrapur
chitosan
upc
deacetyl
degre
comparison
valu
pei
molecular
weight
kda
intratrach
instil
polyplex
mostli
found
airway
central
lung
pei
transfect
seen
effect
longer
last
upc
compar
cation
lipid
consid
safe
pulmonari
applic
provid
chitosan
use
ultrapur
form
known
pathogen
invad
human
bodi
mucos
epithelia
nasal
oral
pulmonari
herebi
airborn
bacteri
viral
infect
lung
tract
eg
influenza
measl
tuberculosi
major
reason
high
rate
death
per
annum
fight
lung
infect
pulmonari
deliveri
vaccin
mimic
natur
way
infect
might
therefor
appropri
way
prevent
anim
model
aerosol
deliveri
involv
intratrach
instil
insuffl
use
exposur
chamber
wherea
clinic
trial
deliveri
devic
requir
micros
particl
size
gener
drypowd
inhal
aerosol
liquidsuspend
particl
nebul
deliv
respiratori
tract
histori
aerosol
vaccin
appli
human
subject
centuri
includ
aerosol
vaccin
anthrax
plaqu
tularemia
smallpox
tetanu
botul
compar
common
parenter
immun
follow
benefit
aerosol
vaccin
matter
discuss
deliveri
vaccin
respiratori
tract
trigger
secret
local
iga
antibodi
turn
capabl
cross
epithelia
prevent
entranc
pathogensth
particular
noninvas
natur
antigen
deliveri
lung
circumv
common
use
needl
syring
main
caus
unsaf
inject
eg
needlestick
injuri
accord
sourc
unsaf
inject
caus
million
case
hepat
b
million
case
hepat
c
million
case
hivaid
around
worldth
applic
pulmonari
drypowd
vaccin
could
stop
common
imper
intact
cold
chain
storag
mandatori
convent
vaccinesfor
administr
vaccin
use
inhal
special
train
medic
personnel
requir
addit
two
independ
studi
infant
underlin
potenti
aerosol
vaccin
highlight
detail
first
schoolchildren
age
south
africa
receiv
measl
vaccin
either
schwarz
ez
vaccin
aerosol
subcutan
sc
administr
month
treatment
aerosol
vaccin
ez
strain
caus
seroconvers
schoolchildren
superior
receiv
subcutan
ez
vaccin
receiv
subcutan
schwarz
vaccin
author
state
method
aerosol
vaccin
might
also
suit
mass
campaign
pediatr
popul
second
studi
measl
vaccin
ez
measlesrubella
administ
mexican
schoolchildren
via
inhal
inject
interestingli
titer
neutral
antibodi
aerosol
group
around
fourfold
greater
comparison
group
receiv
inject
vaccin
moreov
fewer
side
effect
observ
aerosol
inject
administr
vaccin
besid
wongchew
et
al
report
measl
aerosol
vaccin
mexican
infant
stimul
strong
cellular
immun
measur
cytokin
interferongamma
consid
report
find
pulmonari
deliveri
antigen
hold
certainli
promis
immunogen
safe
way
vaccin
prevent
airborn
pathogen
moreov
exceedingli
attract
approach
develop
countri
south
alway
cold
chain
correct
syring
dispos
train
person
guarante
pulmonari
plasmid
dna
vaccin
rather
new
promis
concept
vaccin
might
enabl
futur
immun
intracellular
pulmonari
pathogen
mycobacterium
tuberculosi
respiratori
syncyti
viru
rsv
sever
acut
respiratori
syndrom
coronaviru
sar
vivo
studi
focus
mainli
gene
therapi
lung
expect
rais
effici
safe
pulmonari
gene
deliveri
system
find
applic
also
transport
plasmid
dna
vaccin
regard
deliveri
plasmid
dna
lung
addit
common
intracellular
barrier
gene
therapi
see
fig
extracellular
obstacl
anticip
overcom
eg
withstand
shear
forc
aerosol
cross
respiratori
mucu
layer
cover
conduct
airway
liquid
layer
alveoli
far
pulmonari
deliveri
plasmid
dna
vaccin
report
antigen
see
tabl
differ
research
group
discuss
follow
lombri
et
al
studi
immunogen
two
protein
antigen
ovalbumin
ova
hepat
b
surfac
antigen
hbsag
encod
plasmid
dna
pova
phbsag
intratrach
instil
inject
mice
pulmonari
immun
induc
equipot
cellular
humor
immun
respons
relat
inject
vaccin
interestingli
antigen
plasmid
dna
immun
favor
respons
respect
moreov
bivasbenita
et
al
encapsul
plasmid
dna
vaccin
encod
eight
tcell
epitop
tuberculosi
chitosan
nanoparticl
appli
intratrach
transgen
mice
dna
nanoparticl
elicit
matur
dendrit
cell
dc
stimul
increas
secret
cytokin
comparison
pulmonari
deliveri
plasmid
dna
solut
via
intramuscular
immun
group
evalu
vitro
vivo
immunogen
plasmid
dna
vaccin
encod
latenc
antigen
tuberculosi
formul
poli
llactidecogylcolid
plga
pei
nanoparticl
dna
nanoparticl
matur
human
dc
induc
secret
two
cytokin
similar
extent
posit
control
lipopolysaccharid
lp
prime
mice
nanoparticl
boost
week
protein
enabl
superior
level
cell
prolifer
intramuscular
immun
control
addit
trend
observ
secret
aerosol
deliveri
nanoparticul
conjunct
protein
boost
trigger
highest
releas
far
studi
pulmonari
dna
vaccin
demonstr
next
immunogen
also
protect
efficaci
report
orson
et
al
influenza
antigen
hemagglutinin
ha
viral
strain
express
plasmid
dna
pha
incorpor
pei
particl
aerosol
mice
compar
intraven
deliveri
ha
plasmid
macroaggreg
albumin
maa
pei
particl
less
viru
neutral
antibodi
found
week
postimmun
howev
plasmid
encod
cytokin
granulocytemacrophag
coloni
stimul
factor
gmcsf
coaerosol
pha
pei
particl
signific
increas
neutral
titer
remark
togeth
protect
subsequ
influenza
challeng
fallback
sometim
fatal
sent
gene
therapi
bedsid
back
bench
scenario
applic
nonvir
gene
deliveri
system
appear
advantag
altern
viral
carrier
howev
dilemma
remain
nonvir
deliveri
system
either
toxic
therefor
safe
human
use
much
less
effici
transfect
target
cell
viral
counterpart
hold
true
genet
vaccin
quit
success
anim
studi
dna
vaccin
trial
human
subject
fail
reach
endpoint
establish
protect
immun
top
administr
site
lung
difficult
one
though
rel
access
inhal
toxic
thu
safeti
concern
play
major
role
design
clinic
trial
pulmonari
vaccin
deliveri
although
safeti
measl
vaccin
appli
inhal
shown
introduct
novel
excipi
ultrapur
chitosan
modifi
pei
prove
difficult
context
howev
research
must
continu
develop
novel
gene
therapi
dna
vaccin
carrier
system
especi
lung
challeng
high
success
gene
therapi
cf
achiev
immun
global
killer
tuberculosi
big
benefit
miss
